Novo Nordisk A/S (NYSE:NVO) shares are down during Wednesday’s premarket session. The down move comes as the company announced plans to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027, adding pressure as broader markets edged lower.Novo Nordisk Announces Major GLP-1 Drug Price CutsThe price reduction, announced on Tuesday, will affect popular medications such as Wegovy, Ozempic, and Rybelsus, with the new list price set at $675 per month, down from current prices ranging fro ...

Core Insights - The pharmaceutical giant is entering a partnership with Vivtex to license drug-delivery technologies aimed at developing next-generation oral medications for obesity, diabetes, and related diseases [1] Group 1 - The collaboration focuses on enhancing drug-delivery systems to improve the efficacy of oral medications [1] - The targeted diseases include obesity and diabetes, which are significant health concerns globally [1] - This partnership may position the company to capture a larger market share in the growing sector of oral medications for chronic diseases [1]

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv US tariff rate to hit 15% or more for some nations, USTR says February 25, 20261:11 PM UTCUpdated ago By Reuters Shipping containers are stacked on a cargo ship at the port of Oakland following the Supreme Court's ruling that Trump had exceeded his authority when he imposed tariffs, in Oakland,... Purchase Licensing Rights, opens new tab Read more WASHINGTON, Feb 25 (Reuters) - The U.S. tariff ...

EQT backs out of takeover bid for UK's Oxford Biomedica | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A view shows EQT AB's logo at the company's office in Tokyo, Japan May 13, 2025. REUTERS/Miho Uranaka [Purchase Licensing Rights, opens new tab]Feb 25 (Reuters) - Private equity group EQT [(EQTAB.ST), opens new tab] said on Wednesday it had decided not to proceed with a takeover offer for Oxford Biomedica [(OXB.L), opens new tab] ...

Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Novo Nordisk A/S]Follow[Vivtex Corporation]FollowFeb 25 (Reuters) - Danish drugma ...

Core Viewpoint - Novo Nordisk, once a leader in the GLP-1 weight loss drug market, is facing significant challenges, including pricing pressure, competition, and setbacks in its drug pipeline, leading to a substantial decline in stock value [1][10][14]. Market Position and Competition - Novo Nordisk's market share has decreased to approximately 40%, while Eli Lilly has captured about 60% of the market [2]. - The company is aware of the competitive landscape and pricing challenges, with CEO Mike Doustdar indicating that sales are expected to decline before recovering [2][11]. Financial Performance - The combined sales of Novo's two major drugs, Ozempic and Wegovy, reached around $32 billion, constituting about 67% of total sales last year [6]. - In contrast, Eli Lilly's top two drugs generated approximately $37 billion, representing 56% of its total sales [6]. - Novo Nordisk anticipates a sales and profit decline of 5% to 13% in 2026, marking the first annual sales drop since 2017 [16]. Stock Performance - Novo's stock has plummeted by 75% from its peak of over 1,000 Danish kroner per share in mid-2024, while Eli Lilly's stock has surged by 400% during the same period [13][14]. Future Prospects - The company is pinning hopes on new products like the Wegovy pill and CagriSema to drive future growth, although recent trial results for CagriSema have raised doubts about its commercial viability [17][18]. - The competitive landscape is expected to intensify as other large-cap pharmaceutical companies plan to enter the weight loss drug market with differentiated offerings [17].

Novo Nordisk A/S (NYSE:NVO) announced plans on Tuesday to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027.The price reduction will affect the obesity injection Wegovy, its pill counterpart, the diabetes shot Ozempic, and the oral diabetes drug Rybelsus. The new list price for these medications will be $675 per month, a significant drop from their current prices, which range from $1,027 to $1,350 per month.According to Millar, out-of-pocket costs for commercially insured pati ...

Skip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivBMW to recall nearly 59,000 vehicles in US over damaged wiring harness, NHTSA saysFebruary 25, 20268:26 AM UTCUpdated 5 mins agoBy ReutersThe BMW logo is seen during the 2016 New York International Auto Show in Manhattan, New York, March 24, 2016. REUTERS/Eduardo Munoz/File Photo Purchase Licensing Rights, opens new tabCompaniesBayerische Motoren Werke AGFeb 25 (Reuters) - BMW (BMWG.DE), opens n ...

Welcome back to Market on Close. I'm Marley Caden here in Chicago alongside Sam Bodis at the New York Stock Exchange. Some final thoughts on the session from both of us.For me, of course, an update to the saga that I love. The Warner Brothers Discovery acquisition drama back in focus after the company confirmed it received a higher takeover bid from Paramount Skyance, escalating the bidding war with Netflix. Paramount is trying to top Netflix's roughly 2775 per share agreement with its enhanced proposal tha ...

Just when you think Novo Nordisk A/S ( NVO ) can't go any lower, it gets some more bad news, and the stock dips further.James Foord is an economist by trade and has been analyzing global markets for the past decade. He leads the investing group The Pragmatic Investor where the focus is on building robust and truly diversified portfolios that will continually preserve and increase wealth. The Pragmatic Investor covers global macro, international equities, commodities, tech and cryptocurrencies and is designe ...